Evaxion Biotech AS (NASDAQ:EVAX) is a pioneering entity concentrated on leveraging artificial intelligence (AI) to discover and develop novel immunotherapies for cancer, infectious diseases, and autoimmune disorders. Operating at the intersection of biotechnology and AI, Evaxion aims to revolutionize the way diseases are treated by harnessing the power of the human immune system, guided by cutting-edge computational platforms. The company's projects span a wide range of applications, from personalized cancer vaccines to broad-spectrum antibacterials, with the objective to significantly improve patient outcomes by making therapies more effective, safer, and accessible. Committed to innovation, Evaxion is driven by a fervent desire to address unmet medical needs, positioning itself as a forward-thinking player in the biotech industry.